Education
About Us
Working with TipRanks
Follow Us
Takeda Pharmaceutical Company (TAK)
NYSE:TAK
| Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | ¥ 4.58T | ¥ 4.26T | ¥ 4.03T | ¥ 3.57T | ¥ 3.20T |
| Gross Profit | ¥ 3.00T | ¥ 2.83T | ¥ 2.78T | ¥ 2.46T | ¥ 2.20T |
| Operating Income | ¥ 342.59B | ¥ 214.07B | ¥ 490.50B | ¥ 460.84B | ¥ 509.27B |
| EBITDA | ¥ 1.21T | ¥ 1.14T | ¥ 1.28T | ¥ 1.18T | ¥ 983.72B |
| Net Income | ¥ 107.93B | ¥ 144.07B | ¥ 317.02B | ¥ 230.06B | ¥ 376.00B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | ¥ 405.59B | ¥ 472.89B | ¥ 553.70B | ¥ 875.00B | ¥ 1.00T |
| Total Assets | ¥ 14.25T | ¥ 15.11T | ¥ 13.96T | ¥ 13.18T | ¥ 12.91T |
| Total Debt | ¥ 4.52T | ¥ 4.84T | ¥ 4.38T | ¥ 4.35T | ¥ 4.64T |
| Net Debt | ¥ 4.13T | ¥ 4.39T | ¥ 3.85T | ¥ 3.50T | ¥ 3.67T |
| Total Liabilities | ¥ 7.31T | ¥ 7.83T | ¥ 7.60T | ¥ 7.49T | ¥ 7.74T |
| Stockholders' Equity | ¥ 6.94T | ¥ 7.27T | ¥ 6.35T | ¥ 5.68T | ¥ 5.17T |
| Cash Flow | |||||
| Free Cash Flow | ¥ 856.39B | ¥ 235.61B | ¥ 343.47B | ¥ 937.07B | ¥ 774.46B |
| Operating Cash Flow | ¥ 1.06T | ¥ 716.34B | ¥ 977.16B | ¥ 1.12T | ¥ 1.01T |
| Investing Cash Flow | ¥ -367.06B | ¥ -463.86B | ¥ -607.10B | ¥ -198.13B | ¥ 393.53B |
| Financing Cash Flow | ¥ -751.42B | ¥ -354.42B | ¥ -709.15B | ¥ -1.07T | ¥ -1.09T |